Celgene (NASDAQ:CELG) fights the sell-off
This CEO performance shows that CELG has my sort of management team. That's in contrast to the CEO of a different biotech company with a similar long-term stock chart who closed the Q4 conference call by responding to a question about when growth would resume beyond 2017 this way:
But at this point, I'm not going to give you a point in time when that's going to happen.
That inspired no confidence amongst investors.
Whereas, CELG has sold off from the high $120s to the $114 range on some issues, and it has responded with some new news. No guarantees - it's biotech! - but in my humble opinion, the parrying of the bears was well done, appropriate, and very well-timed.
Here's the background of what I see having weighed on CELG the past couple of months, followed by CEO Mark Alles taking the sellers on with facts and informed projections. As you know, CELG is a strong cash flow company, iconic to many investors, and it's a very large cap name. It could take the passive approach to its stock price, but I think that it wants to nip in the bud the image that the nattering nabobs of negativism have been painting on the company.
Top Biotech Stocks To Own For 2019: Sibanye Gold Limited(SBGL)
Advisors' Opinion:- [By Dan Caplinger]
Tuesday saw a quieter session on Wall Street than Monday, with most major benchmarks modestly increasing to recover some of the ground lost in yesterday's sell-off. Bullish investors are focusing on the likelihood of continued sharp gains when companies report their second-quarter earning in the next month, believing that those results could spur another push higher for stocks. Yet some companies had bad news that sent their shares lower. Hertz Global Holdings (NYSE:HTZ), Sibanye-Stillwater�(NYSE:SBGL), and Achaogen (NASDAQ:AKAO) were among the worst performers on the day. Here's why they did so poorly.
- [By Maxx Chatsko]
Shares of Sibanye-Stillwater (NYSE:SBGL), formerly Sibanye Gold Limited, fell over 11% today after news that a worker died at its Driefontein mining operation in South Africa. As reported by News24, over 20 workers have died at mines owned by the company this year, which is nearly half of all mining industry deaths in the country.
- [By Paul Ausick]
Sibanye Gold Ltd. (NYSE: SBGL) traded down about 1.6% Thursday and posted a new 52-week low of $3.75 after closing Wednesday at $3.81. The stock’s 52-week high is $10.60. Volume totaled around 3 million, about 15% below the daily average. The company had no specific news. Another stock that has turned it around today and looks to close about 1% higher.
- [By Ethan Ryder]
Here are some of the news headlines that may have impacted Accern’s rankings:
Get Just Energy Group alerts: Zacks: Analysts Anticipate Just Energy Group Inc (JE) Will Post Quarterly Sales of $708.65 Million (americanbankingnews.com) Brokerages Expect Just Energy Group Inc (JE) Will Post Earnings of $0.08 Per Share (americanbankingnews.com) 200 days simple moving average (SMA200) Indicator under Review: TrovaGene, Inc. (NASDAQ:TROV), Just Energy … (stocksnewspoint.com) Now Are The Time To Reconsider Sibanye Gold Limited (NYSE:SBGL), Histogenics Corporation (NASDAQ:HSGX … (journalfinance.net)JE traded down $0.04 on Tuesday, hitting $3.65. The company had a trading volume of 188,786 shares, compared to its average volume of 274,492. Just Energy Group has a 1-year low of $3.53 and a 1-year high of $5.91. The company has a debt-to-equity ratio of 1.83, a quick ratio of 1.23 and a current ratio of 1.25. The firm has a market cap of $549.06 million, a P/E ratio of 3.09 and a beta of 0.75.
- [By Neha Chamaria]
Gold prices have been all over the place in the past one year, but some gold stocks have moved in only one direction: south. As of this writing, Canada-based gold miner Eldorado Gold (NYSE:EGO) is down a whopping 66% in one year. South African miner Sibanye-Stillwater�(NYSE:SBGL) is swiftly closing in, having shed as much as half its value with the bulk of the decline coming in just the past couple of months. Among the larger gold miners, Kinross Gold (NYSE:KGC) is down about 11% in one year, or 15% year to date.
Top Biotech Stocks To Own For 2019: Insperity, Inc.(NSP)
Advisors' Opinion:- [By Shane Hupp]
Get a free copy of the Zacks research report on Insperity (NSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Naturally Splendid Enterprises Ltd (CVE:NSP) insider Sead Hamzagic sold 141,500 shares of the company’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of C$0.21, for a total value of C$29,715.00.
- [By Logan Wallace]
Atlantic Trust Group LLC trimmed its holdings in shares of Insperity Inc (NYSE:NSP) by 16.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,152 shares of the business services provider’s stock after selling 5,491 shares during the period. Atlantic Trust Group LLC owned approximately 0.07% of Insperity worth $1,958,000 at the end of the most recent quarter.
- [By Joseph Griffin]
Shares of Insperity Inc (NYSE:NSP) have been given a consensus rating of “Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $86.75.
- [By Logan Wallace]
Insperity (NYSE: NSP) and ASGN (NYSE:ASGN) are both mid-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.
Top Biotech Stocks To Own For 2019: Vanguard Information Technology ETF (VGT)
Advisors' Opinion:- [By Timothy Green, Nicholas Rossolillo, and Todd Campbell]
Luckily, three of our Motley Fool investors are here to help cut through the noise. If you're looking to beat the market, the Vanguard Information Technology ETF (NYSEMKT:VGT) and Vanguard Healthcare ETF (NYSEMKT:VHT) give you the potential to do just that. If instead you just want to match the market's performance, the Vanguard Total Stock Market ETF (NYSEMKT:VTI) is your best bet. Here's what you need to know about these three options.
- [By Shane Hupp]
Dubuque Bank & Trust Co. trimmed its stake in shares of Vanguard Information Technology ETF (NYSEARCA:VGT) by 4.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,740 shares of the exchange traded fund’s stock after selling 1,045 shares during the quarter. Dubuque Bank & Trust Co.’s holdings in Vanguard Information Technology ETF were worth $3,718,000 at the end of the most recent quarter.
- [By Demitrios Kalogeropoulos, George Budwell, and Dan Caplinger]
With those attractive characteristics in mind, we asked Motley Fool investors to highlight a few of the most attractive index funds. Read on to find out why Vanguard Information Technology (NYSEMKT:VGT), Vanguard Total Stock Market Index (NYSEMKT:VTI), and Vanguard Health Care Fund (NASDAQMUTFUND:VGHCX)�all made the list.
No comments:
Post a Comment